Tag Archives: VRX

Top 10 Canadian Stocks To Buy Right Now

There are a number of great companies in the market today. The ModernGraham valuation model selected some of the most undervalued Canadian companies. Each company has been determined to be suitable for the Defensive Investor or the Enterprising Investor according to the ModernGraham approach.

Defensive Investors are defined as investors who are not able or willing to do substantial research into individual investments, and therefore need to select only the companies that present the least amount of risk. Enterprising Investors, on the other hand, are able to do substantial research and can select companies that present a moderate (though still low) amount of risk. Each company suitable for the Defensive Investor is also suitable for Enterprising Investors.

Celestica Inc. (TSX:CLS)

Celestica is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the small size, low current ratio, insufficient earnings stability or growth over the last 10 years and the poor dividend history. The Enterprising Investor is only concerned with the lack of dividends. As a result, all Enterprising Investors should feel comfortable proceeding with the analysis.

Top 10 Canadian Stocks To Buy Right Now: 3M Company(MMM)

Advisors’ Opinion:

  • [By Paul Ausick]

    3M Company (NYSE: MMM) traded down 1.05% at $210.38. The stock’s 52-week range is $163.85 to $214.57. Volume was about 20% below the daily average of around 1.8 million. The company had no specific news.


    Who are the likely candidates for the next round of upgrades? Cramer said he’s betting that 3M (MMM) will be in the mix, along with Walmart (WMT) and especially Home Depot (HD) , which should have a strong spring planting season with good comparisons to last year. Investors might also see upgrades on Honeywell (HON) and Nike (NKE) , Cramer suggested.

  • [By Dustin Blitchok]

    Morrison’s resignation came about one hour after 3M Co (NYSE: MMM) CEO Inge Thulin pulled the plug.

    In a Wednesday statement on his departure from what’s formally known as the Manufacturing Jobs Initiative, Thulin said the group “is no longer an effective vehicle” for the technology company to promote job growth in the U.S.

  • [By Ben Levisohn]

    Time To Favor Optionality: Most macro data are similar to, or better than, when the merger was announced. As a result, the same returns have been obtainable, with significantly less stress, simply through owning 3M (MMM) or a basket of chemical companies that approximate the Dow-DuPont portfolio. Relative to the chemical sector, performance has been average, leverage appears reasonable but near-term FCF less-than compelling partly due to new capacity ramping. With the merger likely to close in the near-term (90% chance, in our view), we believe Dow-DuPont will have an opportunity to show how scale creates optionality. The overhaul at Celanese (CE) over the past few years shows the way.

  • [By Paul Ausick]

    3M Company (NYSE: MMM) traded up 1.38% at $198.50. The stock’s 52-week range is $163.85 to $199.90. Volume was about 35% lower than the daily average of around 1.9 million shares. The company had no specific news Monday.

Top 10 Canadian Stocks To Buy Right Now: Plains All American Pipeline L.P.(PAA)

Advisors’ Opinion:

  • [By Dustin Parrett]

    We think Plains All American Pipeline L.P. (NYSE: PAA) is one of the best oil stocks to buy this year. In fact, we see a scenario where PAA stock could jump 20% in 2017.

  • [By Matthew DiLallo]

    One of the largest projects is the Saddlehorn Pipeline, which Magellan is building with Plains All American Pipeline (NYSE:PAA) and Anadarko Petroleum (NYSE:APC). Both Plains All American Pipeline and Magellan own 40% of the project, which puts their total investment at $230 million apiece. They expect the project to be fully operational early next year, which is noteworthy given its robust first-year economics. Magellan estimates that it will earn eight times EBITDA on the capital deployed, or roughly $28.8 million in annual EBITDA apiece for Magellan and Plains All American Pipeline on their investment.

  • [By Dustin Parrett]

    Plains All American Pipeline (NYSE: PAA) controls 4 million barrels of crude oil and natural gas a day.

    And with higher oil prices and fewer restrictions leading to more drilling, PAA’s pipelines will be in demand in 2017.

Top 10 Canadian Stocks To Buy Right Now: Valeant Pharmaceuticals International Inc(VRX)

Advisors’ Opinion:


    Originally published Nov. 17 at 3:41 p.m. EDT

    The consideration of the contrary has been a theme all week. And here in ” Don’t Run With the Crowd: Embrace the Contrary.”   Miami madness (of a real estate kind)   Mark Grant is scared by our currency’s strength.   Danielle on scenarios.   Boockvar to subscriber Bad Golfer!   JC Penney ( JCP) short puts–a 100% win. (Shorting options frequently ends differently!)   Just say no to closed-end muni-bond funds.   DRYS is all wet.   Could iPhone manufacturing be coming back home?   On inflation breakevens–a picture that speaks volumes.   The market moved higher from the “get go”–in large measure it seems to be a response to the better economic data this morning.   At 3 p.m. stocks were near the day’s highs.   I shorted The Cisco Kid last night. Sticking with this short rental. I added to my ProShares UltraShort S&P500 ETF ( SDS) long (growing ever larger). My net short exposure–is now between small and medium-sized at the close. The U.S. dollar, as discussed above, continued to rip higher against the euro. I am concerned. Mark Grant is concerned. The market is not concerned. The price of crude oil (down $0.20) settled lower after yesterday’s robust gains. Gold fell $9 as it continues to break down–closing in on $1,200. Ag commodities: wheat up $0.07, corn up $0.04, soybeans up $0.05 and oats up $0.02. Lumber up $7 following the big housing number this morning. Bonds schmeissed … iShares Barclays 2

  • [By Paul Ausick]

    Valeant Pharmaceuticals International Inc. (NYSE: VRX) dropped about 3.7% Tuesday to post a new 52-week low of $10.08 after closing Monday at $10.47. The stock’s 52-week high is $38.50. Volume of about 14 million shares was about 30% below the daily average of around 19 million. The company said on Monday that CEO Joseph Papa took home total compensation of nearly $63 million as the stock was losing 62% of its value. The numbers speak for themselves.

  • [By Chris Lange]

    Valeant Pharmaceuticals International, Inc. (NYSE: VRX) has been in the spotlight for a couple years and is now fighting to stay alive. The company initially brought in new executives and tried new initiatives to turn around the company but shares still have dropped. In its most recent attempt, Valeant announced that it intends to refinance some of its debt. One key analyst thinks that this might be a sign to abandon ship.

  • [By Ben Levisohn]

    If it feels like it’s been all Valeant Pharmaceuticals International (VRX) today, I get it, and I promise this will be my last post on the company today. But really, how often do we get to see a fund manager acknowledge a spectacular mistake in such publicfashion?

    Photo: Andrew Harrer/Bloomberg

    As if it weren’t obvious yet, Ackman’s exit is bad news for the stock.Yes, some analysts have tried to focus on other issues that could be positive, but, really, as long as Ackman was around, you knew someone big had Valeant’s back. And now he’s gone. We at Barron’s were never too enthusiastic about Valeant–Vito Racanelliwrote bearishly on the company 2014–or Ackman’s involvement. But it he was your reason to be in Valeant, well consider what Wells Fargo analyst David Maris has to say:

    …we believe investors will take Pershing Squares exit as a reflection that 1) the outlook is negative; 2) the potential for meaningful near-term asset sales is unlikely; 3) the legal proceedings/investigations may have greater risk than the Street is appreciating; 4) a turnaround will take longer than expected or is not possible; and 5) the debtholders have an advantaged position in the capital structure, and as such the equity holders are at their mercy, especially in a bankruptcy situation. We believe investors would consider this as a sign that the next several years may not represent a major turnaround for the company.

    Shares of Valeant have dropped 11% to$10.76 at 3:12 p.m.

  • [By Kumar Abhishek]

    After a horrible 2016, 2017 had started on a good note for shareholders of specialty pharma company Valeant Pharmaceuticals Intl Inc(NYSE:VRX). With the rising optimism around the asset restructuring plan, VRX stock was up more than 10% in the first few days of the year. However, since then Valeant Pharma stock has lost its momentum. Valeant stock is down more than 25% YTD. Shares of the Laval, Qubecbased company were hit hard by the company’s disappointingguidance for 2017. Valeant stock is down by more than 35% since its latest earnings report on February 28th.

Top 10 Canadian Stocks To Buy Right Now: ConocoPhillips(COP)

Advisors’ Opinion:

  • [By Dustin Parrett]

    Big Oil stocks are the seven “oil supermajors” that do everything from oil drilling to refining to retail sales. This is a list of the Big Oil companies:

    Big Oil CompanyShare PriceYTDMarket CapExxon Mobil Corp. (NYSE: XOM)$83.44-7.58%$353.13BChevron Co. (NYSE: CVX)$113.56-3.5%$217.62BConocoPhillips Co. (NYSE: COP)$48.21-3.78%$61.42BRoyal Dutch Shell Plc. (NYSE ADR: RDS.A)$52.35-3.82%$221.08BBP Plc. (NYSE ADR: BP)$34.12-8.71%$112.69BTotal SA (NYSE: TOT)$50.26-1.35%$124.6BEni SpA (NYSE: E)$31.51-2.3%$58.69B

    Despite being huge global oil companies, shares of Big Oil stocks are all in the red this year. Those losses have all happened even as the Dow is smashing record highs and trading up 6.4% year to date.


    In the Lightning Round, Cramer was bullish on Salesforce.com (CRM) , Paccar (PCAR) , Cummins (CMI) , ConocoPhillips (COP) , Adobe Systems (ADBE) , Annaly Capital (NLY) and Hewlett Packard Enterprise (HPE) .

  • [By Chris Lange]

    The number of ConocoPhillips (NYSE: COP) shares short increased to 15.87 million from the previous level of 13.22 million. Shares were trading at $44.10, within a 52-week range of $38.19 to $53.17.

Top 10 Canadian Stocks To Buy Right Now: Safeway Inc.(SWY)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows shares of small cap SUPERVALU now underperforming large cap Kroger Co (NYSE: KR) while shares of large cap Whole Foods Market, Inc (NASDAQ: WFM) and mid cap Safeway Inc (NYSE: SWY) appear to be back to where they started at:

  • [By Peter Graham]

    A long term performance chart shows shares of SUPERVALU underperforming the underperformance ofmid caps Whole Foods Market, Inc (NASDAQ: WFM) and Safeway Inc (NYSE: SWY). while large capKroger Co (NYSE: KR)had outperformed up until the last two years when performance has been more mixed:

Top 10 Canadian Stocks To Buy Right Now: Talisman Energy Inc.(TLM)

Advisors’ Opinion:

  • [By Jayson Derrick]

    On the other hand, the analysts are Underweight on Eni SpA (ADR) (NYSE: E), Repsol Oil & Gas Canada Inc (USA) (NYSE: TLM) and OMV AG given their asset bases, which offer an inferior risk to reward profile and limited differentiation in cost reductions.

Top 10 Canadian Stocks To Buy Right Now: Transcananda Pipelines Ltd.(TRP)

Advisors’ Opinion:


    Energy stocks were driven by a hefty dose of M&A during the third quarter. And that will drive returns for TransCanada Corporation (TRP) during the next one.

  • [By Matthew DiLallo]

    Energy infrastructure companies ONEOK (NYSE:OKE) and TransCanada (NYSE:TRP) are both emerging from the energy market downturn as stronger entities. Each made smart acquisitions, with TransCanada buying U.S. gas pipeline company Columbia Pipeline Group, while ONEOK is in the process of gobbling up its MLP,ONEOK Partners (NYSE:OKS). While these deals enhanced the growth profiles of both companies, TransCanada still stands out as the better buy for long-term income investors. Here’s why.

  • [By Matthew DiLallo]

    After a series of setbacks in its attempts to build new oil pipelines, Canadian pipeline giant TransCanada (NYSE:TRP) completed a transformation transaction to acquire U.S. natural gas pipeline company Columbia Pipeline Group for $13 billion, which includes the assumption of debt. The key to that deal was that it increased the combined company’s near-term project pipeline to 23 billion Canadian dollars, which supports TransCanada’s ability to increase its dividend by 8% to 10% annually through 2020. After completing that deal, TransCanada made a bid to acquire all of the outstanding units that it did not own of affiliated MLP Columbia Pipeline Partners (NYSE:CPPL) in a transaction valued at $915 million. These acquisitions solidified TransCanada’s natural gas pipeline growth ambitions, enabling it to diversify away from oil pipelines.

Top 10 Canadian Stocks To Buy Right Now: Encana Corporation(ECA)

Advisors’ Opinion:


    In the Lightning Round, Cramer was bullish on Vodafone Group (VOD) , Schlumberger (SLB) , Encana (ECA) , Arconic (ARNC) and AdvanSix (ASIX) .

    Cramer was bearish on U.S. Silica Holdings (SLCA) .

  • [By Paul Ausick]

    Encana Corp. (NYSE: ECA) is rated Buy with an unchanged price target of $16. The EPS estimate for 2017 was lowered from $0.42 to $0.34, and the 2018 estimate was also lowered, from $1.47 to $1.28. The shares ended the weekat $11.44, in a 52-week range of $4.90 to $13.85. The consensus 12-month price target is $14.95.

  • [By Money Morning News Team]

    Canada-based Encana Corp. (NYSE: ECA) was the eighth top oil company stock in 2016, with a 131% gain over the year. ECA and its subsidiaries focus on developing, exploring, producing, and marketing natural gas, liquefied natural gas, and oil in North America.

Top 10 Canadian Stocks To Buy Right Now: NEW GOLD INC.(NGD)

Advisors’ Opinion:

  • [By Dan Caplinger]

    The stock market lost ground on Monday, sending major market benchmarks lower by more than half a percentage point. The Dow lost its grip on the 20,000 mark in the wake of concerns about economic growth and new U.S. immigration policy, and some believe that the broader geopolitical climate could have a negative impact on global commerce that in turn could start affecting multinational corporations’ business prospects. In addition, bad news from some individual companies weighed on the markets, and Transocean (NYSE:RIG), Rite Aid (NYSE:RAD), and New Gold (NYSEMKT:NGD) were among the worst performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so poorly.

Top 10 Canadian Stocks To Buy Right Now: Silver Wheaton Corp(SLW)

Advisors’ Opinion:

  • [By Rich Duprey]

    Silver Wheaton (NYSE:SLW), of course, is a streamer like Sandstorm and Franco, but it is the largest in the precious-metals industry, and arguably the best-known, because its business model came to define what streaming is. Although it is known primarily for its silver contracts, Silver Wheaton also has sizable gold production that makes it worth your attention.

Valeant Stock: The Rally May Be Over, But The Struggle Is Not

Valeant Stock: The Rally May Be Over, But The Struggle Is Not - Valeant Pharmaceuticals Intl Inc

Despite posting strong results, the troubles for Canada based specialty pharma company Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is far from over. In the last two trading sessions, shares of Canada basedtroubled drug makerhave lost over 7% after the company came out with a plan to raise more than $750 million in debt in a private offeringof 5.5% notes due in 2025. Valeant will use a part of the proceeds to pay down term loans due in 2022.

The recent correction has brought back Valeant stock below the 100-day moving average line. 100-day SMA hasprovided strong resistance to Valeant stock in past. Valeant stock has been unable to breach the 100-day SMA resistance line despite several attempts. The stock hadgone above the resistance line recently, propelled by the better than expected earnings, but is back below the trend line once again. The resistance from 100-day SMA is likely to keep a check on any rally in Valeant stock for now.
VRX Technical chart

Green shoots are visible.

Earlier, Valeant Pharma had posted better than expected top and bottom line numbers. Valeant had reported an adjusted EPS of $1.04, 16 cents higher than analysts estimate of an adjusted EPS of $0.88. Valeant Revenues came in $2.22 billion, $50 million higher than expected. Strength in its Bausch and Lomb eye-care business helped Valeant Pharma in delivering strong performance. Moreover, Valeant maintained its full-yearadjusted EBITDA guidance of $3.60 billion to $3.75 billion,despite divesting assets to reduce its debt pile.The company has also bought itself some breathing room by eliminating all long-term debt maturities until 2020 and all mandatory amortization requirements.

Valeant Pharma free cash flow and long term debt

On GAAP basis the company reported Net Profit of$1.30 billion, compared to a loss of $1.22 billion in the comparable quarter last year. That’s a remarkable improvement. It reduced total debt by about $6 billion between the end of the first quarter of 2016 and Nov. 7 and has exceeded its goal of paying down $5 billion in debt by February 2018. Valeant stock rallied by over 27.7% on the strong performance before correcting the last two trading sessions.
VRX net income chart

Valeant has still a long way to go.

However, it’s not all hunky-dory for Valeant. Despite beating the estimates, revenues were down by over 10% YoY and the remarkable improvement in Net Income was driven mainly by a tax benefit of about $1.4 billion. The poor performance of itsU.S. diversified products and branded businesses haveinvestors worried. Also, despite paying off $6 billionin debt, Valeant still has a boat load of debt sitting on its balance sheet. On September 30, the company had little over $27 billion in long-term debt. And the financial leverage has not improved.To quote Wells Fargos David Maris:

“The company highlighted several times how it has paid down debt ahead of its own schedule, but according to our estimates, leverage is higher now than it was a year ago or last quarter. Total debt to TTM adj. EBITDA by our calculation is now 7.20x vs. 6.65x a year ago, and is also higher sequentially (vs. 7.15x in 2Q17).”

There are concerns thatValeant revenues and margins could decline further in 2018 as more drugs with high margin face LOEs. Add to the fact that, R&D spending declined by 20% YoY, the chances of Valeant producing multiple winners in-house looks dim and the company is unlikely to go for acquisition once again. Its Dermatology segment is far from stable.Dermatology sales declined 34% YoY. The company also indicated thatmore likely than not, its tax burden is likely to increase in future, further eroding its margins. And the proposed tax reform could have a significant impact on Valeant, especiallyfrom the proposed 20% excise tax. In addition,Valeant continues to have a wide array of pending suits and ongoing investigations which could have a significant impact on the company’s financials.

Turnaround is still far away.

The current management led by Joe Papa has done a good job in reducing Valeant’s massive debt burden and bringing some stability to the core business. Valeant has also made some progress in getting Siliq and Vyzulta approved. The company expects the addressable market for Vyzutla to be around $1.6 billion dollar market. “Valeant is a very different company today than it was a year ago,” CEO Papa had said in a statement. And he is right. However, the turnaround is still far away. A lot will depend onVRX’s ability to meaningfully improve revenue trends for Xifaxan and the Dermatology business. Valeant stock continues to remain highly volatile and risky.

Facebook is part of ourtop stocks to buylist which have outperformed the Nasdaq Composite by over 165%. Further, if you’re also looking for top picks from the auto sector, you should also check out ourtop auto stock picks, which have beaten the S&P 500 by over 269%.If you’re a trader though, you should check out ourdaily trading ideas sectionfor daily, free updates on the latest crossovers and other popular technical signals